ESPR: the balance sheet

MyFinsight

For the quarter ending 2025-09-30, ESPR has $364,020K in assets. $815,381K in debts. $92,447K in cash and cash equivalents.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Balance Sheets	2025-09-30	2025-06-30
Cash and cash equivalents	92,447	86,061
Accounts receivable, net	118,980	107,746
Inventories, net	108,539	114,466
Prepaid clinical development costs	2,791	4,170
Prepaid inventory costs	33,299	24,772
Other prepaid and current assets	4,408	5,380
Total current assets	360,464	342,595
Property and equipment, net	175	201
Right of use operating lease assets	3,325	4,233
Intangible assets	56	56
Total assets	364,020	347,085

Accounts payable	77,513	74,704
Convertible notes, net of issuance costs	54,863	54,766
Accrued clinical development costs	1,619	1,209
Accrued variable consideration	78,508	61,299
Other accrued liabilities	18,641	15,455
Royalty sale liability	94,826	66,312
Deferred revenue from collaborations	30,679	22,313
Operating lease liabilities	2,384	2,738
Total current liabilities	359,033	298,796
Convertible notes, net of issuance costs	97,128	96,998
Royalty sale liability	199,364	229,600
Long-term debt	151,653	146,452
Operating lease liabilities	767	1,312
Other long-term liabilities	7,436	7,436
Total liabilities	815,381	780,594
Common stock, 0.001 par value 480,000,000 shares authorized as of september30, 2025 and december31, 2024 207,424,417 shares issued at september30, 2025 and 197,846,661 shares issued at december31, 2024	205	200
Additional paid-in capital	1,288,974	1,275,498
Treasury stock, at cost 1,994,198 shares at september30, 2025 and december 31, 2024	54,998	54,998
Accumulated deficit	-1,685,542	-1,654,209
Total stockholders deficit	-451,361	-433,509
Total liabilities and stockholders deficit	364,020	347,085